Flu and COVID-19: When is Novavax’s combo vaccine coming?

The flu and COVID-19 pose health risks, especially for people with previous illnesses, pregnant women or the elderly. The US company Novavax has developed a combination vaccine intended to protect against SARS-CoV-2 and seasonal influenza, and initial studies with human subjects are already underway.

The combination vaccine from  Novavax  could be particularly suitable as a booster vaccination for older people or patients at risk.

Novavax combination vaccine: how it works

The vaccine candidate “Covid-NanoFlu Combination Vaccine” consists of the protein-based  corona vaccine  from Novavax (NVX-CoV2373) and the influenza vaccine NanoFlu™ as well as the enhancer (adjuvant) Matrix-M:

  • Corona vaccine from Novavax in a nutshell:  The vaccine is based on an artificially produced protein mix that also contains the spike protein of the  coronavirus  . This protein enables the virus to dock onto human cells. The artificially produced spike protein can be injected directly into the body. After vaccination, the body perceives the protein particles as foreign bodies and begins to fight the virus. Antibodies and T-cells are produced, which develop their protective effect in the event of an actual infection.
  • NanoFlu™, the flu vaccine from Novavax:  NanoFlu™ is also based on a protein mix composed of portions of the circulating wild-type  influenza virus  and various influenza virus strains.

In previous studies, Novavax was able to demonstrate the effectiveness of the combination vaccine. However, this was a combination of the Corona vaccine from Novavax and a flu vaccine from Sequirus.

Influenza and corona vaccine: study is already underway

The first volunteer was vaccinated last week. A total of 640 healthy people between the ages of 50 and 70 will take part in the study in Australia. The subjects are either already vaccinated with an approved COVID-19 vaccine or have recovered.

The combination vaccine is to be given twice, 56 days apart. The first results of the combination vaccine are to be published in the first half of 2022.


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *